CapeXL is an end-to-end solution for personalised cancer treatment, providing next-generation sequencing (NGS), analysis, annotation and reporting to clinicians.

The service is patient-focused, matching individuals to the latest options in treatment including approved drugs, drugs with evidence in early and late stage clinical trials and pre-clinical models approved for cancers.

For example:

  • Trastuzumab approved for HER2 therapy
  • tumour mutation burden for immunotherapy
  • mutation signatures: homologous recombination for platinum-based therapy or PARP inhibitors
  • mis-match repair for immunotherapy: Keytruda.

We make ordering and reporting simple for clinicians, so they can support their patients in a personalised way.

Whole genome sequencing (WGS) supports better patient outcomes with the complete picture and detecting variants precisely.

A 2018 study found WGS improves “comprehensiveness and accuracy” of variant detection, cancer treatment and outcomes. *

* Article published in Nature Communications by Rusch et al (2018), page 2.

Our analysis and pipeline service

Get in contact to order

The Full Picture

Other products and services

CapeQ4

Software as a service to support central lab analysis for cancer profiling

Learn more

CapeVR

Analysis and reporting for cancer profiling, including TMB from provided NGS data

Learn more